Travere Therapeutics Inc, TVTX, FDA Calendar, PDUFA Date

Company Name	Travere Therapeutics Inc TVTX
Drug Name	FILSPARI (sNDA)
Event Name	FDA decision on FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS)
Event Date	04/13/2026
Outcome Date	04/13/2026
Outcome	FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis without nephrotic syndrome on Apr.13, 2026
Drug Status	FILSPARI is developed by Travere in collaboration with Ligand Pharma
Rival Drugs	If approved, FILSPARI would be the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure
Market Potential
Other Approvals	FILSPARI is already approved by the FDA to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.
News

Return to FDA Calendar

Slide Shows